• 1
    James WPT. The epidemiology of obesity: The size of the problem. J Intern Med 2008;263:336352.
  • 2
    Joliffe D. Continuous and robust measures of the overweight epidemic: 1971–2000. Demography 2004;41:303314.
  • 3
    Berghöfer A, Pischon T, Reinhold T, Apovian MA, Sharma AM, Willich SN. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008;8:200.
  • 4
    Asia Pacific Cohort Studies Collaboration. The burden of overweight and obesity in the Asia Pacific region. Obes Rev 2007;8:191196.
  • 5
    World Health Organization. World Health Statistics 2012. Geneva: WHO; 2012. pp 3637.
  • 6
    McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight and obese individuals. Metabolism 2004;53:495499.
  • 7
    Wilson PWF, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Arch Intern Med 2002;162:18671872.
  • 8
    Tsigos C, Hainer V, Basdevant A, et al. Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008;1:106116.
  • 9
    Rodgers RJ, Tschöp MH, Wilding JPH. Anti-obesity drugs: past present and future. Dis Model Mech 2012;5:621626.
  • 10
    Moreira FA, Crippa JAS. The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 2009;31:145153.
  • 11
    Williams G. Withdrawal of sibutramine in Europe. Br J Med 2010;340:c824.
  • 12
    Yun JW. Possible anti-obesity therapeutics from nature—A review. Phytochemistry 2010;71:16251641.
  • 13
    Drewnowski A, Kurth C, Holden-Wiltse J, Saari J. Food preferences in human obesity: Carbohydrates versus fats. Appetite 1992;18:207221.
  • 14
    Barrett ML, Udani JK. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): A review of clinical studies on weight loss and glycemic control. Nutr J 2011;10:2433.
  • 15
    Santimone M, Koukiekolo R, Moreau Y, et al. Porcine pancreatic alpha-amylase inhibition by the kidney bean (Phaseolus vulgaris) inhibitor (alpha-AI1) and structural changes in the alpha-amylase inhibitor complex. Biochim Biophys Acta 2004;1696:181190.
  • 16
    Celleno L, Tolaini MV, D'Amore A, Perricone NV, Preuss HG. A dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. Int J Med Sci 2007;4:4552.
  • 17
    Wu X, Xu X, Shen J, Perricone N, Preuss H. Enhanced weight loss from a dietary supplement containing standardized Phaseolus vulgaris extract in overweight men and women. J Appl Res 2010;10:7379.
  • 18
    Udani J, Hardy M, Madsen DC. Blocking carbohydrate absorption and weight loss: A clinical trial using Phase 2™ brand proprietary fractionated white bean extract. Altern Med Rev 2004;9:6369.
  • 19
    Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595605.
  • 20
    Wilcox CS, Oskooilar N, Ericksom JS, et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav 2010:35:229234.
  • 21
    EFSA Panel on Dietetic products, Nutrition and Allergies (NDA). Guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations. EFSA J 2012;10:2604 (11 pp).
  • 22
    Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004;79:347349.
  • 23
    Grievink L, Alberts JF, O'Niel J, Gerstenbluth I. Waist circumference as a measurement of obesity in the Netherlands Antilles; associations with hypertension and diabetes mellitus. Eur J Clin Nutr 2004;58:11591165.
  • 24
    Stevens VL, Jacobs EJ, Sun J, et al. Weight cycling and mortality in a large prospective US study. Am J Epidemiol 2012;175:785792.
  • 25
    Lahti-Koski M, Männistö S, Pietinen P, Vartiainen E. Prevalence of weight cycling and its relation to health indicators in Finland. Obes Res 2005;13:333311.
  • 26
    Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein and carbohydrates. N Engl J Med 2009;360:859873.
  • 27
    Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:11941199.
  • 28
    Lichtman SW, Pisarska K, Berman ER, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med 1992;327:18931898.
  • 29
    Scagliusi FB, Polacow VO, Artioli GG, et al. Selective underreporting of energy intake in women: Magnitude, determinants, and effect of training. J Am Diet Assoc 2003;103:13061313.